EXPRESS MAIL CERTIFICATE

Express Mail" mailing label number

EL 984 914 472 US

Date of Deposit

May 20, 2004

Type of Documents

Information Disclosure Statement;

Form 1449 (3 pages);

Cited References / two (2); and

Return Postcard

Serial No.

10/692,105

Filing Date

October 23, 2003

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and are addressed to the Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450.

(signature)





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Bradley, et al.

Examiner: To be assigned

Serial No.:

10/692,105

Art Unit: 1654

Filed:

October 23, 2003

Docket No.:

B185 1015.1

•

For:

Process for the Production of a

Reversibly Inactive Acidified Plasmin

Composition

(MSC 8009.5)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Post Office Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants hereby voluntarily disclose the references listed on the attached Form PTO-1449 to the Commissioner for Patents. This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits of the application. Accordingly, it is believed that no fees are due. However, should any fees be due, the Patent Office is hereby authorized to charge Deposit Account No. **09-0528**.

Also, in addition to the references listed on Form PTO-1449, Applicants wish to call the Examiner's attention to copending U.S. Appln. No. 10/143,156; 10/143,112; 10/143,157; and 10/280,444. These applications and the above-captioned application claim priority to original parent Appln. No. 09/438,331 (now U.S. Patent No. 6,355,243).

Copies of two references (F1 and D24) are provided herewith. Applicants have not provided copies of the remaining references in this submission because the remaining references are either U.S. patent documents or are believed to be available in the file of patent

Appln No. 10/692,105 EL 984 914 472 US

Appln. No. 10/143,156. However, applicants will provide copies of any references should they be requested by the Examiner.

Applicants further reserve the right to establish the patentability of the claimed invention over any of the listed information should they be applied as references, and/or to prove that some of the cited information may not be prior art, and/or to prove that some of the cited information may not be enabling for the teachings they purport to offer. This statement further should not be construed as the representation that an exhaustive search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of the information, and to form independent opinions as to their significance.

It is respectfully requested that the Examiner initial and return copies of the enclosed PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

Date: May 20, 2004

Attorney for Applicants Registration No. 44,224

Docket: **B185 1015.1** (MSC 8009.5)

Womble Carlyle Sandridge & Rice, PLLC Post Office Box 7037 Atlanta, Georgia 30357-00378 Telephone (336) 721-3681 Facsimile(336) 726-8074



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Attorney Docket No.	Serial No. 10/692,105			
B185 1015.1				
Applicant				
Bradley, et al.				
Filing Date	Group			
October 23, 2003	1654			

_					October 2	23, 2003	1654	
*	·		U.S.	PATENT DOCUM	MENTS			
Examiner Initials	Item	Document Number	Date	Name	e	Class	Subclass	Filing Date If Appropriate
	P1	6,479,253	11/2002	Silver, e	et al.			
	P2	6,139,819	10/31/00	Unger, e	et al.			
	Р3	5,879,923	3/9/99	Yago, e	t al.			
	P4	5,776,452	7/7/98	Eibl, et	al.			
	P5	5,767,269	6/1998	Hirsh, e	t al.		•	
	P6	5,728,674	1998	Sprecher,	et al.			
	P7	5,472,692	12/5/95	Liu, et	al.			
	P8	5,407,673	1995	Reich, e	t al.			,
	P9	5,328,996	7/1994	Boyle	e			
	P10	5,304,383	4/19/94	Eibl, et	al.			
	P11	5,290,692	3/1994	Suzuki, e	et al.			
	P12	5,288,489	2/1994	Reich, e	t al.			
	P13	5,165,912	11/1992	Selmer, e	et al.			
	P14	5,024,829	6/1991	Berger, e	et al.			·
	P15	4,908,204	3/1990	Robinson,	, et al.			
-	P16	4,774,087	9/1988	Wu, et	al.			
	P17	4,663,146	5/1987	Morser, e	et al.			
	P18	4,462,980	7/1984	Diedrichser	n, <i>et al</i> .			
•	P19	4,446,316	5/1984	Chazov,	et al.			
	P20	4,442,213	4/1984	Heber, e	et al.			
	P21	4,361,653	11/1982	Watanabe,	, et al.			
	P22	4,361,652	11/1982	Uemura,	et al.			
	P23	4,177,262	12/1979	Lormeau,	et al.			
	P24	4,082,612	04/1978	Robbins,	et al.			
	P25	3,950,513	04/1976	Jense	n			
	P26	3,434,929	03/1969	Buck. e	t al.			

	-			FORE	EIGN PATENT DOCUMENTS						
		Document Number		Date	Date Country		Subclass	Translation			
		Num						Yes	No		
•	Fl	EP 0:	256836 A1	08/87	ЕРО						
			OTHER DOC	UMEN'	ΓS (Including Author, Title, Date, Pertin	ent Pages, e	tc.)				
		D1	Ambrus, C., et al.,	ʻInsolubi	lized Activators of the Fibrinolysin System	m," <i>J. Med</i>	3: 270-281 (19	72).			
D3 Amris, C.J., et al., "I Cancer," Danish Me. D4 Amris, C.J., et al., "I Read to the Cancer," Danish Me. Bulletin, 11(5): 146-					"Clinical Pharmacology of various types of fibrinolytic enzyme preparations," Am. J. (1960). Effect of Plasmin Therapy on Blood Coagulation and on Plasma Proteins in Patients with edical Bulletin, 11(5): 141-145 (1964).						
					Furnover and Distribution of ¹³¹ I-Labelled Procine Plasmin in Man and Dog," <i>Danish Medical</i> 152 (1964).						
				"Experiences with Fibrinolysin in Peripheral Vascular Occlusive Disease," Am. J. Cardiol., 6:							
				.J., et al., "The Electrophoretically 'Slow' and 'Fast' Forms of the α2-Macroglobulin Molecule," J., 181: 401-418 (1979).							
				"Segmental Perfusion of the Coronary Arteries with Fibrinolysin in Man Following a ion," Am. J. Cardiol., 6: 525-533 (1960).							
		D8	Boyles, P.W., et al. Cardiol., 6: 439-44		arative effectiveness of intravenous and ir	tra-arterial f	ibrinolysin the	rapy," Am	. <i>J</i> .		
		D9	Castellino, F.J. and	J.R. Pow	ell, "Human Plasminogen," Meth. Enzym	ology, 80: 3	65-378 (1981)	•			
experimental jugular vein thrombosi				r vein th	lysis with human extrinsic (tissue-type) prombosis. Effect of molecular form and d of Clin. Invest., 71(2): 368-376 (1983).				, and		
			Deutsch, D.G. and E.T. Mertz, "Plasminogen: purification from human plasma by affinity chromatography," Science 170: 1095-1096 (1970).								
		D12			minogen as an Adjunct to Local Intra-arte dings," Neuroradiology, 38: 181-185 (199		ysis of Carotid	Territory	Stroke:		
		D13	Hedner, U., et al., " 51(1): 157-164 (19		f Porcine Plasmin on the Coagulation and	l Fibrinolytic	Systems in H	umans," E	Blood,		
,		D14			oral Vein Catheter with Immobilized Urcatif. Intern. Organs, 33: 136-139 (1987).	kinase (UKI	FC) as an Anti	thrombotic	Blood		
		D15	Larsen, V., "Fibrino 140 (1964).	olytic En	zyme in the Treatment of Patients with Ca	ancer," Dani.	sh Medical Bu	lletin, 2(5)): 137-		
		D16	Larson, V., et al., ". 89): 34-73 (1966).	Fibrinoly	tic Treatment with Activator-Free Porcin	e Plasmin,"	Scand. J. Clin.	Invest. 18	(Suppl.		
		D17	Lijnen, H.R., et al.,	"Activat	ion of plasminogen by pro-urokinase," J.	Biol. Chem.	, <i>261(1)</i> : 1253	-1258 (19	86).		
D18 Lippschutz, E.L., et plasmin," Am. J. Ca					Controlled study of the treatment of coronary occulsion with urokinase-activated human 16:93-98 (1965).						

	D19	Moser, K., "Effects of Intravenous Adminis (1959).	tration of Fibrinolysin (Plasmin) in Man," Circulation, 20: 42-55				
	D20	Mizutani et al. "Potential thrombolysis under selective infusion of autolotous plasmin (AP) solution," Japanese Heart Journal, 30(5): 723-732 (1989).					
	D21	Nilsson, T. and B. Wiman, "On the structure of the stable complex between plasmin and alpha-2-antiplasmin," <i>FEBS Lett.</i> , 142(1): 111-114 (1982).					
	D22		ial of locally delivered active plasmin (Pm): In vitro assessment and in lar vein trombosis model," <i>Blood, J. of the Am. Soc. of Hematology</i> , 998).				
	D23	Robbins, K.C. and L. Summaria, "Plasminogen and Plasmin," Meth. Enzymol. 45: 257-273 (1976).					
	D24	Robbins, K.C., et al., "Purification of human plasminogen and plasmin by gel filtration on Sephadex and chromatography on Diethylaminoethyl-Sephadex, <i>The Journal of Biological Chemistry</i> , 238(3): 952-962 (1963).					
	D25	Sherry, S., "The Origin of Thrombolytic Therapy," J. Am. Coll. Cardiol., 14(4): 1085-1092 (1989).					
	D26	Verstraete, M., "The Fibrinolytic System: from Petri Dishes to Genetic Engineering," <i>Thrombosis and Haemostasis</i> , 74(1): 25-35 (1995).					
	D27	Wiman, B., "Affinity-chromatographic puris (1980).	fication of human alpha 2-antiplasmin," Biochem. J., 191(1): 229-232				
		tation considered, whether or not citation is in co red. Include copy of this form with next commun	nformance with MPEP § 609. Draw line through citation if not in all all all all all all all all all al				
EXAMINER'S S	IGNATU	JRE:	DATE CONSIDERED:				

WINSTON 1308422v1